|Hmmm, maybe so.|
I find it hard to understand why investors would prefer drugs used to treat rare diseases instead of drugs used to treat very common diseases.......
I recall the conference call following the announcement, and the Rocket guys described some of the diseases they were trying to treat. He said stuff like "About 1,000 people per year contract this disease....."
How you going to justify a $500 million market cap curing 1,000 people per year?
Anyway, I'm out of ITEK, but I still have all my GRV.